Search

everythinglearnresearchcommunity

for

Search:↓

The study created special nanoparticles that effectively deliver an anti-inflammatory drug to treat skin inflammation in psoriasis.

Omalizumab may cause hair loss.

Ocrelizumab may cause total body hair loss in some patients.

A young woman had a rare skin reaction to a medication for her joint disease, and a combination therapy improved her condition.

Bimekizumab can improve scarring alopecia in severe psoriasis.

A patient with Crohn's disease grew back their hair after stopping Adalimumab, which had caused hair loss.

Pembrolizumab can cause serious liver issues, requiring close monitoring and early treatment.

Budesonide is not effective for maintaining remission in Crohn's disease beyond three months.

Baricitinib improved hair loss and arthritis in a lupus patient.

Belatacept may be a promising treatment for alopecia areata.

A patient with multiple sclerosis developed skin reactions after Daclizumab treatment, requiring more data on the drug's effects.

Ixekizumab effectively treats generalized pustular psoriasis.

Teriflunomide is effective and generally safe for treating relapsing-remitting multiple sclerosis.

Adalimumab significantly improves quality of life for patients with moderate to severe hidradenitis suppurativa.

Tocilizumab therapy may cause skin and hair conditions like halo naevi, vitiligo, and alopecia areata.

Teriflunomide effectively reduces relapses and disability in MS and has a manageable safety profile.

Rituximab may cause skin issues, but baricitinib can help improve them.

A woman with rheumatoid arthritis lost all her hair during adalimumab treatment, and stopping the drug didn't help.

Brodalumab is more effective than ustekinumab in treating psoriasis.

Teriflunomide effectively reduces relapse rates and disease progression in multiple sclerosis but is not safe for use during pregnancy.

Anifrolumab improves quality of life and reduces steroid use in lupus patients.

Adalimumab may cause severe hair loss in some patients.

Tocilizumab might be an effective treatment for COVID-19.

Tildrakizumab significantly improved psoriasis symptoms and well-being over 52 weeks.

Adalimumab was safe but mostly ineffective for severe alopecia areata.

Baricitinib is effective and cost-efficient for treating severe alopecia areata in adults.

Canakinumab's effect on COVID-19 outcomes is unclear.

A woman developed hair loss after starting a treatment with adalimumab, suggesting this medication might cause hair loss.

The antibody 005-C04 blocks prolactin receptors, causing reversible infertility, impaired lactation, and hair regrowth in female mice.